The Medicines and Healthcare products Regulatory Agency (MHRA) is considering issuing precautionary advice for people with a history of capillary leak syndrome.
The medicines regulator has clarified that it does not see a causal link between the syndrome and AstraZeneca’s Covid-19 vaccine following a statement from the European Union that it was a rare side effect of the shot.
MHRA chief executive June Raine said that two of eight reports of capillary leak syndrome following AstraZeneca vaccination were in people with a history of the condition, and 40 million doses of the vaccine had been given.
Raine added: “The incidence of these reports is lower than the number of cases expected to occur by chance in the absence of vaccination of this extremely rare condition and the current evidence does not suggest that capillary leak syndrome is caused by the Covid-19 Vaccine AstraZeneca,” she said.
“Whether or not a precautionary advice is warranted for patients who have previously experienced capillary leak syndrome is currently being carefully considered by the MHRA as well as the independent Commission on Human Medicines’ Covid-19 Benefit/Risk Expert Working Group.”
The MHRA said on Thursday (June 10) that it “had received eight reports of capillary leak syndrome in the context of more than 40 million doses of the AstraZeneca vaccine given, and currently does not see a causal link.”
